Pre-exposure prophylaxis for HIV infection may be effective in older candidates, but proceed with caution
- 56 Downloads
The effectiveness and safety of tenofovir (TDF)-based therapy, which is the standard for pre-exposure prophylaxis (PrEP) for HIV infection, have not been specifically evaluated in older individuals. Major concerns relate to the older population being predisposed to kidney- and/or bone-related adverse events if they receive TDF-based PrEP. However, TDF-based PrEP may be a manageable treatment option in older candidates if careful screening, regular monitoring and appropriate sexual health education are also incorporated into the prevention plan.
Compliance with ethical standards
Conflict of interest
The article was adapted from Drugs & Aging 2018;35(6):485–91  by employees of Adis/Springer, who are responsible for the article content and declare no conflicts of interest.
The preparation of this review was not supported by any external funding.
- 11.Anderson PL, Liu AY, Castillo-Mancilla JR, et al. Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following directly observed therapy. Antimicrob Agents Chemother. 2018;62(1):e01710–7.Google Scholar
- 12.Wright E, Grulich A, Roy K, et al. Australasian Society for HIV, viral hepatitis and sexual health medicine HIV pre-exposure prophylaxis: clinical guidelines. J Virus Erad. 2017;3(3):168–84.Google Scholar
- 14.European AIDS Clinical Society. Guidelines for treatment of HIV-positive adults in Europe (version 9): 2017. http://www.eacsociety.org/. Accessed 13 Aug 2018.